SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Business
TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2014 Financial Results And Business Update
March 10, 2015
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 27th Annual ROTH Conference
March 6, 2015
 · 
1 min read
Business
TG Therapeutics, Inc. Enters Into A Global Collaboration With Checkpoint Therapeutics To Develop And Commercialize Novel Immuno-Oncology Targeted Antibodies
March 4, 2015
 · 
6 min read
Pharm Country
TG Therapeutics, Inc. To Present At The Cowen and Company 35th Annual Health Care Conference
March 2, 2015
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
February 4, 2015
 · 
1 min read
Biotech Bay
TG Therapeutics, Inc. To Provide An Update On Its Clinical Programs And Corporate Goals For 2015 At The 33rd Annual J.P. Morgan Healthcare Conference
January 15, 2015
 · 
4 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 33rd Annual J.P. Morgan Healthcare Conference
January 8, 2015
 · 
1 min read
Business
TG Therapeutics, Inc. Announces Appointment Of Kenneth Hoberman To Board Of Directors
December 17, 2014
 · 
5 min read
Drug Development
TG Therapeutics, Inc. Release: Preliminary Data From Ongoing Phase I/II Dose Escalation Study Of TG-1101 (Ublituximab) In Combination With TGR-1202 In Heavily Pre-Treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity A
December 9, 2014
 · 
12 min read
Drug Development
TG Therapeutics, Inc. Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)
December 9, 2014
 · 
9 min read
Drug Development
TG Therapeutics, Inc. Release: Interim Data From Phase 1 Dose Escalation Clinical Trial Of TGR-1202, The Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity And Lack Of Hepatic Toxicity In Patients With Relapsed/Refractory Chronic
December 8, 2014
 · 
10 min read
Business
TG Therapeutics, Inc. Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib (Imbruvica) For Patients With Select B-Cell Malignancies
December 1, 2014
 · 
5 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 2014 Deutsche Bank BioFEST Conference
November 26, 2014
 · 
1 min read
Business
TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
November 11, 2014
 · 
9 min read
Business
TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2014 Financial Results And Business Update
November 10, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 56th American Society of Hematology Annual Meeting
November 6, 2014
 · 
6 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS